I created this blog in 2021 because I wanted to offer a place where I can objectively share information related to dementia. My current research is focused on workplace dementia and the employee experience. However, employees and their families who have gone through this experience know it is so much more than just what happened on the job. It's really about the "what now?", "what's next?", and "how do we (I) do this?"
In the last few posts, I focused on Adulhelm, because early on many people saw this medication as an effective treatment for Alzheimer's disease (AD). The excitement around the FDA's approval and initial launch brought a lot of hope to many, many families. Unfortunately, it brought false hope and so much disappointment for families who are willing to try anything to help their loved ones. I thought it was important to share what I found to be a troubled FDA approval process, misleading data and (from my perspective) a desperate attempt to hurry SOMETHING/ANYTHING to market! Hence my focus...
In future posts, I will include experiences of people who were experiencing cognitive impairments at work and in some cases, those who were not yet diagnosed. I will share their stories and the impact on their families, friends and their concerns about what is to come. I hope you find these experiences interesting and important as there is more to dementia than simply forgetting things.
Chris
Komentarze